A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation
详细信息    查看全文
文摘
ss="listitem" id="list_ulist0010">
ss="label">•

Alemtuzumab has an overall response rate of 67% as a second-line agent for steroid-refractory acute graft-versus-host disease

ss="label">•

Higher alemtuzumab levels on day 6 from first alemtuzumab dose were associated with complete response.

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址:北京市海淀区学院路29号 邮编:100083

电话:办公室:(+86 10)66554848;文献借阅、咨询服务、科技查新:66554700